Abstract:Polo-like kinase 1 (Plk1) belongs to a subfamily of Ser/ Thr protein kinases, collectively termed polo-like kinases (Plks). A growing body of evidence suggests that Plk1 plays important roles during multiple stages of M-phase progression and, as a result, in cell proliferation. In a series of preclinical studies, PLK1 has been validated as a cancer target. This has prompted many research scientists to develop selective PLK1 inhibitors for the treatment of cancer. The recent strategy employed in PLK1 inhibition involves the designing of small molecule inhibitors that targets the classical ATP-binding site of PLK1. Purpurogallin (PPG) and poloxin have been reported as inhibitors of the polo-box domain (PBD) of human polo-like kinase 1. Recently, new generation of PLK1 inhibitors targeting the second druggable domain of PLK1, the polo box domain, is currently being tested preclinically. We propose to design and develop 1, 3-thiazolidin-4-ones which could inhibit PLK1 for potent anticancer and anti-inflammatory activities. The 1, 3-thiazolidin – 4-ones could show anticancer and anti-inflammatory potential through inhibition of polo-like kinase 1 (PLK1) and cyclooxygenase-2 (COX 2) via NF-Kb (nuclear factor kappa-light- chain-enhancer of activated B cells) protein. Molecular docking of a set of ligands was performed using Vlife MDS 4.4 software. The 3D ligand protein complex structure of Polo Like Kinase 1 (2rku) was obtained from the protein database bank (RCSB-PDB) and processed for protein preparation and optimization. The computational studies suggest that aromatic group with non-polar electronegative substituents at second position and nitro-heterocycle either directly or through amide linkage at third position of the 1, 3-thiazolidin – 4-ones could result in better anticancer compound through inhibition of enzyme polo-like kinase 1.

Aromatic dihydrazide type PLK1 (Polo-like Kinase 1) inhibitor and applications thereof

Aromatic Diacylhydrazine Derivatives As a New Class of Polo-Like Kinase 1 (PLK1) Inhibitors.

Exploring Novel PLK1 Inhibitors Based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Identification of Nitroimidazole-Oxime Derivatives Targeting the Polo-Box Domain of Polo-Like Kinase 1.

Molecular Docking Studies of 1, 3- Thiazolidin-4-Ones as Potential Human Polo Like Kinase 1 (Plk 1) Inhibitors

Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)

Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.

Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells

Identification of PLK1-PBD Inhibitors from the Library of Marine Natural Products: 3D QSAR Pharmacophore, ADMET, Scaffold Hopping, Molecular Docking, and Molecular Dynamics Study

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

QSAR study of tetrahydropteridin derivatives as polo-like kinase 1(PLK1) Inhibitors with molecular docking and dynamics study

Identification of Acylthiourea Derivatives As Potent Plk1 PBD Inhibitors.